|
EP4793360A2
(en)
|
2006-03-31 |
2026-08-19 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
|
EP3127921A1
(en)
|
2007-09-26 |
2017-02-08 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substition in cdr
|
|
TW201920257A
(zh)
|
2008-04-11 |
2019-06-01 |
日商中外製藥股份有限公司 |
重複結合複數個抗原的抗原結合分子
|
|
TWI654203B
(zh)
|
2010-11-30 |
2019-03-21 |
Chugai Seiyaku Kabushiki Kaisha |
具有鈣依存性的抗原結合能力之抗體
|
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
|
EA201791366A1
(ru)
|
2014-12-19 |
2018-02-28 |
Чугаи Сейяку Кабусики Кайся |
Антитела к c5 и способы их применения
|
|
MX2017005774A
(es)
|
2014-12-19 |
2017-07-28 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
|
|
CN114773469B
(zh)
|
2015-02-05 |
2025-12-19 |
中外制药株式会社 |
包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
|
|
CA3024618A1
(en)
|
2016-05-27 |
2017-11-30 |
Alexion Pharmaceuticals, Inc. |
Methods for treatment of refractory generalized myasthenia gravis
|
|
IL263481B2
(en)
|
2016-06-14 |
2024-06-01 |
Regeneron Pharma |
Anti-c5 antibodies and uses thereof
|
|
CN116271014A
(zh)
|
2016-08-05 |
2023-06-23 |
中外制药株式会社 |
用于预防或治疗il-8相关疾病的组合物
|
|
EP3592386A4
(en)
|
2017-03-06 |
2021-01-13 |
The Trustees Of The University Of Pennsylvania |
ANTI-C5 ANTIBODIES AND USES THEREOF
|
|
ES2965486T3
(es)
*
|
2017-07-27 |
2024-04-15 |
Alexion Pharma Inc |
Formulaciones de anticuerpos anti-C5 de alta concentración
|
|
MX2020003619A
(es)
*
|
2017-10-04 |
2020-10-28 |
Alexion Pharma Inc |
Dosificacion y administracion de los anticuerpos anti-c5 para el tratamiento de los pacientes con glomerulonefritis membranoproliferativa.
|
|
JP7518764B2
(ja)
|
2017-10-26 |
2024-07-18 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
発作性夜間ヘモグロビン尿症（ＰＮＨ）および非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量および投与
|
|
AU2018383751B2
(en)
|
2017-12-13 |
2025-05-08 |
Regeneron Pharmaceuticals, Inc. |
Anti-C5 antibody combinations and uses thereof
|
|
EP3802593B1
(en)
|
2018-05-31 |
2024-09-11 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
|
|
EP3802603A1
(en)
*
|
2018-06-04 |
2021-04-14 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients
|
|
JP7538723B2
(ja)
|
2018-06-28 |
2024-08-22 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
抗ｃ５抗体の産生方法
|
|
CN113038967B
(zh)
|
2018-09-06 |
2026-07-14 |
宾夕法尼亚大学理事会 |
人源化抗c5抗体及其用途
|
|
US12240893B2
(en)
*
|
2018-10-30 |
2025-03-04 |
Alexion Pharmaceuticals, Inc. |
Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH)
|
|
CN116194478A
(zh)
|
2020-06-24 |
2023-05-30 |
阿雷克森制药公司 |
皮下（sc）施用抗c5抗体治疗补体相关病症
|